When Genentech joined in the anti-IgE program in 1996, the original 2-way Tanox-Ciba Geigy agreement was expanded to a tripartite agreement. A joint steering committee formed by members from the three companies chose omalizumab (trade name Xolair) developed by Genentech for further development, on the basis that it had a better developed manufacturing process than TNX-901.
When Genentech participated in the anti-IgE program in 1996, the original agreement between Tanox and Ciba Geigy was broadened into a partnership. A joint committee formed by members from all three companies chose omalizumab (marketed as Xolair) developed by Genentech for further development, based on its superior manufacturing process compared to TNX-901.